AUA

“We recommend doing the spot cautery,” says Andrew Higgins, MD.

“Even in patients that have only been single-stone formers, especially those that have required surgical stone removal, we believe that medical prevention is warranted to prevent recurrent stones,” says Glenn M. Preminger, MD.

Men whose activity exceeded guideline-based exercise levels experienced a decreased likelihood of lower serum testosterone, according to study results presented at the American Urological Association 2020 Virtual Experience.

The FDA recently granted approval for Jelmyto, which is the first therapy for the treatment of low-grade upper tract urothelial cancer. Urology Times® spoke with Angela B. Smith, MD, MS, regarding the significance of this approval for providers and patients.

Misinformation about prostate cancer is rampant online and significantly impacts patient care, study authors said at an American Urological Association press briefing. Researchers using machine learning have taken what they say is a first step to help vet the quality of online content.

Findings from a study characterizing the providers and services offered by stand-alone commercialized men’s health clinics should be eye-opening and alarming for urologists, said Jagan K. Kansal, MD, MBA, at the American Urological Association 2020 Virtual Experience.

The benefits of minimally invasive water vapor thermal therapy (Rezūm System) on lower urinary tract symptoms due to benign prostatic hyperplasia are durable, with a reduction in symptom score and an improvement in flow rate sustained to 5 years, according to researchers.

Data from a large registry showed that active surveillance for small renal masses was safe and noninferior to primary intervention at 10 years. In this video, senior author Phillip M. Pierorazio, MD, of Johns Hopkins University discusses results of the study presented as part of the AUA 2020 Virtual Experience.

Disease progression within 6 months was the strongest surrogate marker for overall survival in patients with metastatic hormone-sensitive prostate cancer treated with combination therapy in a retrospective analysis of the CHAARTED trial.

Analyses of data from a multi-institutional registry show that blue light cystoscopy using hexaminolevulinate HCl (Cysview) detects invasive bladder tumors that are missed by white light cystoscopy in an appreciable number of patients.

Women with mixed urinary incontinence seeking surgical intervention for refractory urinary urge incontinence have the same low risk of subsequently needing surgery for stress urinary incontinence whether they are treated with intradetrusor onabotulinumtoxinA (BTX [Botox]) injections or sacral neuromodulation.

In this video, Seth P. Lerner, MD, discusses the OLYMPUS Trial of intracavitary UGN-101 (mitomycin gel; Jelmyto) in patients with low-grade upper tract urothelial carcinoma.

Compared with local radiation therapy, radical prostatectomy as primary treatment for prostate cancer may result in a lower risk of castration-resistant disease and superior overall survival from the time of metastasis.

“UGN-101… has the potential to change practice for patients with low-grade renal pelvis cancer,” says researcher John L. Gore, MD.

Researchers found that 30 of 46 study participants (65%) experienced more than a 50% improvement in urgency urinary incontinence with the nickel-sized device.

Increasing the frequency setting on a holmium:YAG laser increases stone fragmentation, but determining the saturation point at which efficiency plateaus requires further study.

The majority of medication prescribed to patients undergoing outpatient urologic procedures goes unused, prospective data reveal.

An analysis of Medicare expenditures in the first year after a diagnosis of prostate cancer shows that 5% of patients account for almost 25% of the total spending.

The use of enzalutamide (XTANDI) and abiraterone acetate (ZYTIGA) show differences in overall survival and health care costs when used to treat chemotherapy-naïve metastatic castrate-resistant prostate cancer.

With the AUA annual meeting quickly approaching, Victor W. Nitti, MD, chair of the AUA Office of Education, provides a snapshot of new course offerings and other AUA educational opportunities.

In advance of this year’s AUA annual meeting, Urology Times asked members of our editorial board to choose the top presentations in their subspecialty.

Ray Painter, MD, and Mark Painter also answer coding questions regarding vasectomy and code 50543.

Men with large prostates experience more relief from BPH with treatment by Aquablation therapy (using the AquaBeam System) than with transurethral resection of the prostate, researchers say.

Many urologists don't follow guidelines calling on them to image their patients after ureteroscopic stone disease treatment, researchers say.

Henry Rosevear, MD, explains how he left the AUA annual meeting in San Francisco a smarter urologist.  

In this interview, Jamin Brahmbhatt, MD, gives his take on several studies of orchialgia and chronic prostatitis/chronic pelvic pain syndrome presented at the 2018 AUA annual meeting.

Arthur L. Burnett, II, MD, MBA, discusses some of the significant differences between the 2018 and 2005 AUA guidelines on ED as well as how the new guideline addresses novel treatments that are not currently FDA approved.

In this video, Benjamin M. Brucker, MD, explains the use of clinical care pathways to manage overactive bladder and outlines the benefits of SUFU’s Overactive Bladder Clinical Care Pathway.

Anne E. Calvaresi, DNP, CRNP, RNFA, also discusses best practices that urologists and APPs can follow to ensure they work together well as a team and offers her opinion on the controversy surrounding the use of APPs for performing certain urologic procedures.

In this video, Alan J. Wein, MD, PhD, discusses recent developments in the management of nocturia, including a new FDA-approved agent; underlying causes; and the role of a voiding diary in patient care.